tbuckley/cabot-search huggingface dataset:
Concomitant Administration of Gene-Modified T Cells Expressing a Chimeric CD16-CD3ζ Receptor with Mogamulizmab Synergistically Suppresses Adult T Cell Leukemia Cells in Vivo
Authors: Kazushi Tanimoto, Hiroshi Fujiwara, Hiroki Tanaka, Fumihiro Ochi, Hiroaki Asai, Sachiko Okamoto, Junichi Mineno, Kiyotaka Kuzushima, Hiroshi Shiku, John Barrett, Masaki Yasukawa
Journal: Blood (2014)
Triptolide-Induced Apoptosis Is Dependent on Caspase Activation and NFκB Signaling and Mediated by XIAP and Survivin Downregulation through the Mitochondrial Pathway in Leukemic Cells.
Authors: Bing Z. Carter, Wendy D. Schober, Teresa McQueen, Randall L. Evans, Michael Andreeff
Journal: Blood (2004)
EPCs Derived from Ex Vivo Expansion of Unmobilized Human Peripheral Blood Co-Express Hematopoietic and Endothelial-Specific Markers and Can Be Derived from Culture of Highly Purified Populations of CD14-Positive Monocytes.
Authors: Emerson E. Sharpe, Amylynn A. Teleron, Bin Li, Pampee P. Young
Journal: Blood (2004)
Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Authors: Gilles Andre Salles, Thomas E Boyd, Franck Morschhauser, Clemens-Martin Wendtner, James Lymp, James Hilger, Gregory Vosganian, Jane Huang, Stephan Stilgenbauer
Journal: Blood (2014)
ONC201 Induces p53-Independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies By Induction of ATF4 through Integrated Stress Response
Authors: Jo Ishizawa, Kensuke Kojima, Dhruv Chachad, Peter Ruvolo, Vivian Ruvolo, Rodrigo Omar Jacamo, Gautam Borthakur, Hong Mu, Zhihong Zeng, Yoko Tabe, Joshua Allen, Zhiqiang Wang, Wencai Ma, Hans Lee, Robert Z. Orlowski, Dos D. Sarbassov, Sattva S. Neelapu, Timothy J. McDonnell, Roberto N. Miranda, Michael Wang, Hagop M Kantarjian, Marina Konopleva, Richard Eric Davis, Michael Andreeff
Journal: Blood (2015)
Abstract 15663: Hyponatremia-Induced Symptomatic Brugada Syndrome Mimicking St Segment Elevation Myocardial Infarction
Authors: Pattara Rattanawong, Jitrada Ungprasert, Vichai Senthong
Journal: Circulation (2018)

Case study: A 73-year-old male with a history of diabetes, hypertension, and stage 3 chronic kidney disease having experienced epigastric pain associated with nausea, vomiting, shortness of breath,...
Miniaturized T2MR Magnetic Resonance System for Analysis of Hemostasis and Detection of Impaired and Prothrombotic Blood Disorders
Authors: Douglas B. Cines, Tatiana Lebedeva, M. Anna Kowalska, Mortimer Poncz, Lubica Rauova, Adam Cuker, John W. Weisel, Walter Massefski, Vyacheslav Papkov, Edward C. Thayer, Thomas J. Lowery
Journal: Blood (2012)
Late Relapse of Localized High-Grade Non-Hodgkin’s Lymphoma: Clinical and Biological Features
Authors: Gandhi Damaj, Marc Bernard, Steven Legouill, Guillaume Cartron, Annie Le Mevel, Céline Dubus, Christian Berthou, Philippe Colombat, Noel Milpied, Jean Pierre Marolleau, Thierry Lamy
Journal: Blood (2008)
High Risk of Pregnancy Related Venous Thromboembolism in Women with a Hereditary Deficiency of Antithrombin, Protein C or Protein S in Concomitance of Other Thrombophilic Defects: A Retrospective Cohort Study.
Authors: Nienke Folkeringa, Jan-Leendert P. Brouwer, Fleurisca J. Korteweg, Nic J.G.M Veeger, Jan Jaap H.M. Erwich, Jan van der Meer
Journal: Blood (2006)
Msi2 Maintains the MLL Leukemia Stem Cell Regulatory Program
Authors: Sun Mi Park, Mithat Gönen, Ly P. Vu, Gerard Minuesa, Patrick Tivnan, Trevor Barlowe, James Taggart, Yuheng Lu, Raquel P Deering, Nir Hacohen, Maria Figueroa, Elisabeth M. Paietta, Martin S. Tallman, Ari M. Melnick, Ross L. Levine, Christina Leslie, Christopher J Lengner, Michael G Kharas
Journal: Blood (2014)
Frequency of Complete Molecular Response In Chronic Myeloid Leukemia Patients In Real Life Practice.
Authors: Matthieu Decamp, Dina Istasi, Atchroue Johnsonansah, Oumedaly Reman, Xavier Levaltier, Christophe Fruchart, Vincent Launay, Seyeffedine Kadi, Xavier Troussard
Journal: Blood (2010)
Downregulation of type I IGF receptor increases insulin sensitivity of breast cancer cells
Authors: Hua Zhang, Alissa M. Pelzer, David T. Kiang, Douglas Yee
Journal: Cancer Research (2006)

4831  The type I insulin-like growth factor (IGF) receptor (IGF1R) is an attractive target for breast cancer intervention. Due to the sequence and structure similarity of IGF1R to its homologous receptor, insulin receptor (IR), great effort has been given to discover inhibitors that only target IGF1R, but not IR. However, since IGF1R and IR form hybrid receptors, we hypothesize that inhibiting IGF1R alone in breast cancer may affect insulin receptor signaling as well. Using ribonuclease protection assay and Western blotting method, we examined 24 breast tumors and found that all breast tumors express both IGF1R and IR. The presence of both IGF1R and IR suggests that IGF1R inhibition might affect IR function in breast cancer. In several breast cancer cell lines, the presence of IGF1R and IR were assayed and the relative ratios of IGF1R vs IR mRNA were calculated. Of the several cell lines studied, while MCF-7 expressed about 10 fold excess of IGF1R compared with IR, LCC6, MDA-MB 231-BO, MDA-MA 231 had equivalent levels of IGF1R and IR mRNA. Therefore, those three cell lines were chosen for further analysis. siRNA sequences that specifically targeting IGF1R or IR were designed. IGF1R and IR expression was specifically decreased by 78% and 97% by the appropriate siRNAs without affecting the protein level of the other receptor. After transfecting cells with IGF1R or IR siRNA for 48 hours, cells were treated with insulin or IGF-I, and phosphorylation of Akt and MAPK was measured to examine downstream signaling events. As expected, decreased levels of IR resulted in diminished activation of MAPK and PI-3K by insulin. siRNA downregulation of IGF1R greatly decreased the ability of IGF-I to activate MAPK and PI-3K pathways. Interestingly, downregulation of IGF1R enhanced the ability of insulin to activate MAPK and PI-3K pathways. Accordingly, the glucose uptake of breast cancer cells was enhanced when IGF1R was downregulated. Using flow cytometry analysis, we found out that insulin binding was increased when IGF1R level was downregulated, suggesting downregulation of IGF1R may cause the disruption of IGF1R/IR hybrid receptor, forcing the balance of more IR homodimer formation. In conclusion, our data suggest that specific targeting of IGF1R alone in breast cancer may increase insulin sensitivity of breast cancer cells. Since IR also activates signaling pathways in breast cancer cells, agents targeting both receptors may be necessary to disrupt the malignant phenotype regulated by this growth factor system.
Sequential Autologous Followed by Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors Improves Outcomes of Patients (pts) with Bulky Lymphoma or Chronic Lymphocytic Leukemia (CLL)
Authors: Mohamed L. Sorror, Barry Storer, Brenda M Sandmaier, Thomas Chauncey, Michael T. Maris, Rainer F. Storb, David G. Maloney
Journal: Blood (2010)
A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Authors: Maria Corinna Palanca-Wessels, Ian W. Flinn, Laurie H. Sehn, Manish Patel, Randeep Sangha, Myron S. Czuczman, Gilles Andre Salles, Franck Morschhauser, Ranjana Advani, Oliver W. Press, William Ho, Robert Kahn, Dan Lu, Zheng Su, Yu-Waye Chu, Sarit E. Assouline
Journal: Blood (2012)
Atrial fibrillation risk loci interact to modulate Ca2+-dependent atrial rhythm homeostasis
Authors: Brigitte Laforest, Wenli Dai, Leonid Tyan, Sonja Lazarevic, Kaitlyn M. Shen, Margaret Gadek, Michael T. Broman, Christopher R. Weber, Ivan P. Moskowitz
Journal: Journal of Clinical Investigation (2019)

Atrial fibrillation (AF), defined by disorganized atrial cardiac rhythm, is the most prevalent cardiac arrhythmia worldwide. Recent genetic studies have highlighted a major heritable component and identified numerous loci associated with AF risk, including the cardiogenic transcription factor genes TBX5, GATA4, and NKX2-5. We report that Tbx5 and Gata4 interact with opposite signs for atrial rhythm controls compared with cardiac development. Using mouse genetics, we found that AF pathophysiology caused by Tbx5 haploinsufficiency, including atrial arrhythmia susceptibility, prolonged action potential duration, and ectopic cardiomyocyte depolarizations, were all rescued by Gata4 haploinsufficiency. In contrast, Nkx2-5 haploinsufficiency showed no combinatorial effect. The molecular basis of the TBX5/GATA4 interaction included normalization of intra-cardiomyocyte calcium flux and expression of calcium channel genes Atp2a2 and Ryr2. Furthermore, GATA4 and TBX5 showed antagonistic interactions on an Ryr2 enhancer. Atrial rhythm instability caused by Tbx5 haploinsufficiency was rescued by a decreased dose of phospholamban, a sarco/endoplasmic reticulum Ca2+-ATPase inhibitor, consistent with a role for decreased sarcoplasmic reticulum calcium flux in Tbx5-dependent AF susceptibility. This work defines a link between Tbx5 dose, sarcoplasmic reticulum calcium flux, and AF propensity. The unexpected interactions between Tbx5 and Gata4 in atrial rhythm control suggest that evaluating specific interactions between genetic risk loci will be necessary for ascertaining personalized risk from genetic association data.
Intra-tumoural perfusion habitats showed prognostic value in glioblastoma patients
Authors: Chao Li, Chang Sun, Shuo Wang, Stephen Price
Journal: Neuro-Oncology (2019)

Abstract The perfusion within glioblastoma is associated with tumour microenvironment and may create invasive tumor habitats that could potentially be revealed by perfusion imaging. The purpose of this study is to characterize the peritumoural habitats of glioblastoma for treatment target. Dynamic susceptibility contrast-enhancement (DSC) MRI was acquired pre-operatively on 115 newly-diagnosed glioblastoma patients. All images were co-registered to post-contrast T1-weighted images. The relative cerebral blood volume (rCBV), mean transit time (MTT) and relative cerebral blood flow (rCBF) maps were generated from the DSC images. The contrast-enhanced and peritumoural tumor regions were semi-automatically segmented from the post-contrast T1-weighted and FLAIR images. To delineate the habitats of different perfusion levels, a two clusters mixture model with Gaussian distribution was fitted to the rCBV, rCBF, and MTT within both contrast-enhanced and peritumoural regions. Perfusion parameters of the identified habitats were compared, and the prognostic values of habitats were investigated using survival analysis. The results showed that although non-enhanced, the peritumoral high perfusion (PHP) habitat demonstrated similar perfusion level with the contrast high perfusion (CHP) habitat, with similar rCBV (PHP: 1.13 ± 0.18, 95% CI [1.10, 1.15]; CHP: 1.21 ± 0.25, 95% CI [1.16, 1.21]) and rCBF (PHP: 1.08 ± 0.23, 95% CI [1.05, 1.08]; CHP: 1.08 ± 0.19, 95% CI [1.05, 1.08]). Multivariate Cox regression showed that the volumes of both habitats were associated with worse patient overall survival (PHP: P = 0.032; HR= 7.09; CHP: P = 0.008; HR= 12.01). Our results suggest that the intra-tumoural perfusion habitats may potentially offer treatment targets.
Clones with and without Sensitivity Towards Treatment In Vivo Co-Exist within the Tumor Cells of a Single Patient with ALL
Authors: Cornelia Finkenzeller, Michela Carlet, Sebastian Vosberg, Christoph Ziegenhain, Martin Neumann, Kristoffer Riecken, Kerstin Cornils, Boris Fehse, Claudia D. Baldus, Wolfgang Enard, Philipp A. Greif, Irmela Jeremias
Journal: Blood (2016)
ZNF384-Fusion Proteins Have High Affinity to EP300, Which Increases Their Transcriptional Activities
Authors: Hideyuki Yamamoto, Fumihiko Hayakawa, Takahiko Yasuda, Yuka Minamikawa, Naoyuki Tange, Daiki Hirano, Yuki Kojima, Takanobu Morishita, Shinobu Tsuzuki, Hiroyuki Mano, Tomoki Naoe, Hitoshi Kiyoi
Journal: Blood (2018)
Development of an MCDA framework for evaluation and positioning of oncological treatments in clinical practice.
Authors: Carlos Camps, Xavier Badia, Divya Chugani, Rosario García Campelo, Jesus Garcia-Foncillas, Rafael Lopez, Bartomeu Massuti, Mariano Provencio-Pulla, Ramon Salazar, Juan Virizuela, Vicente Guillem
Journal: Journal of Clinical Oncology (2019)

95 Background: Ensuring that effective innovations are accessible in a timely and affordable manner to all cancer patients is a challenge that stakeholders face today. Several oncology frameworks (ASCO, ESMO, ICER, NCCN) have been developed to define and quantify the value of oncological therapies to support clinicians and patients at the time of selection and as a basis for decision-making. However, current frameworks only define treatment value in terms of clinical benefit, creating a need for one that allows holistic evaluation of treatments and supports decision-making in clinical practice. The ECO Foundation led this study to develop a reflective multi-criteria decision analysis (MCDA) based framework for evaluation and positioning of new oncological drugs from the clinical oncology perspective. Methods: The framework was developed following EVIDEM methodology. Systematic literature review was performed to identify most relevant criteria used for evaluation of innovative treatments to complement the EVIDEM V4.0 framework. The criteria compendium was presented to a group of clinical oncologists from ECO. The Expert Group assessed each criterion for its inclusion in the framework and suggested modifications in their definition and/or response scale. This framework was then tested with two case studies (Abemaciclib for metastatic HER-/HR+ breast cancer and TAS for metastatic colorectal cancer). The objective was to validate the criteria selected alongside their definitions and response scale with practical examples. A reflective discussion based on the score assigned to each criterion was also carried out. Results: Out of 15 criteria presented to the Expert Group, 8 were included in the final framework, and definition and/or response scale of 7 of these criteria were modified: Disease severity, Unmet needs, Efficacy comparison, Safety/tolerability comparison, Treatment intention, Treatment cost comparison, Comparison of other medical costs and Quality of evidence. Conclusions: A reflective MCDA framework has been developed and validated, based on the value of the treatment, for assessment and positioning of oncological therapies in the context of clinical practice in Spain.
Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation
Authors: Jacques Azzi, Frank Cirrone, Maher Abdul Hay, David Kaminetzky, Kenneth B. Hymes, Maxim Kreditor, Ahmad-Samer Al-Homsi, Michael L. Grossbard, Catherine Diefenbach, Tibor Moskovits, Shella Saint Fleur-Lominy, Bruce G. Raphael, Raoul Tibes
Journal: Blood (2018)
The Therapeutic Response of Myelodsyplastic Syndromes to Azacytidine Is Independent of Endogenous Retroelement Modulation
Authors: Chrysoula Kordella, Anastasiya Kazachenka, Eleftheria Lamprianidou, Emmanouela Zoulia, George Vrachiolias, Menelaos Konstantinos Papoutselis, Zoe Bezirgiannidou, Emmanouil Spanoudakis, Christiana Georgiou, Urszula Eksmond, George Kassiotis, Ioannis Kotsianidis
Journal: Blood (2018)
Reduced Intensity or Non-Ablative Hematopoietic Cell Transplantation in Older Patients with Non-Hodgkin Lymphoma (NHL): Encouraging Survival for Patients ≥55 Years
Authors: Brian McClune, Tanya L. Pedersen, Kwang W Ahn, Erica D Warlick, Joseph Pidala, Edmund K Waller, J. Douglas Rizzo, Mitchell S. Cairo, Ann Woolfrey, Andrew Artz, Hillard M. Lazarus, Daniel J. Weisdorf
Journal: Blood (2011)
Indications and contraindications for mastectomy
Authors: R. S. Handley
Journal: JAMA (1967)

There are no absolute and invariable rules for the treatment of any form of carcinoma in an individual. The general physical state, the psychological stability, and the social circumstances may all modify the accepted treatment for a particular form of malignancy, and what follows concerning the indications and contraindications for mastectomy in stage III carcinoma of the breast is written in the knowledge that there are circumstances under which the advice given must be modified or even disregarded. It is necessary first to consider what we are talking about when we speak of a stage III carcinoma of the breast. First, we are here concerned with clinical staging, as distinct from the more accurate pathologic staging which can only be achieved by hindsight in the light of the histologist's report and which is not, therefore, available when decisions about treatment have to be made. Second, clinical staging is bedeviled by
Improving patient experience in health care and oncology: A scoping review.
Authors: Petra Grendarova, Demetra Hariklea Yannitsos, Marcus Vaska, Lisa Catherine Barbera
Journal: Journal of Clinical Oncology (2019)

209 Background: Patient-reported experience measures (PREMs) gather information directly from patients and capture their perspectives on their health care. Deficiencies identified by PREMs can lead to quality improvement (QI) interventions. The purpose of this review was to identify published and unpublished evidence on initiatives aimed to improve patient experience, to identify their areas of application and their overall impact on patient experience. Methods: We conducted a systematic literature review using MEDLINE (Ovid), EBM Reviews, HealthStar, PsycINFO, PubMed, PubMed Central, CINAHL, MEDLINE (Ebsco), Psychology &amp; Behavioral Sciences, TRIP Database, EMBASE and Web of Science databases and several sources of grey literature. Inclusion criteria required the studies to evaluate an intervention or a systematic change aimed to improve patient experience and measured by a specific PREM. The search was limited to English language reports published between 1998 and 2018. Of the initial 780 articles, 318 were included in abstract reviews. 304 abstracts were excluded leaving 44 records for full text review. Results: 21 records were included in the final analysis (20 journal articles and 1 web report). Publication dates ranged between 2007 and 2018 in the USA, UK, Norway, Denmark, Belgium and Bangladesh. There were 8 QI initiatives, 6 randomized studies, 1 non-randomized trial, 3 mixed methods, 2 repeated cross-sectional studies and 1 national patient experience model. Areas of focus included hospital care, surgery, internal medicine, primary care and oncology. Nine studies had programmatic interventions and 12 had specific interventions. All specific interventions reported positive effects. Outcomes were variable in programmatic interventions, including 5 studies reporting positive effects, 3 neutral and 1 mixed effects. Conclusions: The effect of specific interventions aimed to improve patient experience is positive. There is limited data on the effect of programmatic initiatives and the factors that drive the improvement in patient experience. Such initiatives are needed to understand their impact on patient experience and person-centered care.
Insufficiency of Non-Canonical PRC1 Complex Cooperates with an Activating JAK2 Mutation in the Pathogenesis of Myelofibrosis
Authors: Daisuke Shinoda, Yaeko Nakajima-Takagi, Motohiko Oshima, Atsunori Saraya, Hironori Harada, Haruhiko Koseki, Kazuya Shimoda, Goro Sashida, Atsushi Iwama
Journal: Blood (2018)
Bortezomib in Combination with Cyclophosphamide and G-CSF for Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma
Authors: Bhausaheb Bagal, Anant Gokarn, Avinash Bonda, Swapnil Chavan, Sachin Punatar, Lingaraj Nayak, Sadhana Kannan, Libin J Mathew, Nikhil Patkar, Prashant Tembhare, Minal Poojary, Shashank Ojha, Papagudi Ganesan Subramanian, Sumeet Gujral, Tapan Saikia, Navin Khattry
Journal: Blood (2018)
Discrimination of the behavioural dynamics of visually impaired infants via deep learning
Authors: Erping Long, Zhenzhen Liu, Yifan Xiang, Andi Xu, Jialing Huang, Xiucheng Huang, Xiaoyan Li, Zhuoling Lin, Jing Li, Jingjing Chen, Yan Zhang, Yi Zhu, Chuan Chen, Ziheng Zhou, Xiaowei Ding, Xiaohang Wu, Wangting Li, Hui Chen, Ruiyang Li, Yahan Yang, Weishi Zheng, Weirong Chen, Haotian Lin, Yizhi Liu
Journal: Nature Biomedical Engineering (2019)
Not All T Cell Synapses Are Built the Same Way
Authors: Sudha Kumari, Huw Colin-York, Darrell J. Irvine, Marco Fritzsche
Journal: Trends in Immunology (2019)

T cells comprise functionally diverse subtypes. Although activated via a conserved scheme of antigen recognition by their T cell receptor, they elicit heterogeneous activation and effector responses. Such functional diversity has been appreciated in gene expression studies, functional assays, and disease models. Yet, our understanding of the principles underlying T cell subtype-specific activation and antigen recognition in the immunological synapse remains limited. This is primarily due to difficulties in primary T cell visualization at high spatiotemporal resolution and the adoption of tractable transformed T cell systems for cell biological experiments that may not correctly represent primary T cell constitutional diversity. Here, we discuss recent findings regarding the architectural and dynamic diversity of the immunological synapse and state-of-the-art methodologies that can be utilized to provide clues on how biological and biophysical differences in synaptic make-up could govern functional divergences in T cell subtypes.
Abstract 631: Complementary Roles for 3-mercaptopyruvate Sulfurtransferase and Cystathionine γ-lyase in Angiogenesis
Authors: Athanasia Pavlidou, Sofia-Iris Bibli, Katalin Modis, Noriyuki Nagahara, Csaba Szabo, Ingrid Fleming, Andreas Papapetropoulos
Journal: Circulation Research (2019)

Introduction: Hydrogen sulfide (H 2 S) is a signaling molecule with important actions in the cardiovascular system. The major endogenous sources for H 2 S in the endothelium are cystathionine γ-lyase (CSE) and 3-mercaptopyruvate sulfotransferase (3MST). We have previously shown the CSE-derived H 2 S enhances angiogenesis, however, the role of 3MST in new blood vessel formation remains largely unexplored. Aim: To evaluate the impact of 3MST on angiogenesis and to study the potential mechanisms involved. Methods &amp; Results: 3MST deficient EC exhibited attenuated cell growth, reduced mobility in the scratch wound assay and less sprouting in the fibrin gel bead assay. All of the above-mentioned deficits were less prominent than in cells lacking CSE. In an ex vivo sprouting assay, fewer microvessel-like structures were generated by aortic rings treated with a siRNA directed against 3MST compared to a control oligonucleotide. Similarly, sprouting from 3MST KO aortic rings was less than from wild-type mice. In line with the in vitro responses, angiogenesis in vivo in the Matrigel plug assay and in the retina was reduced in 3MST KO mice, but the decrease was of smaller magnitude compared to that seen with CSE KO mice. The angiogenic switch of EC relies mainly on glycolysis, therefore glycolytic intermediates and TCA metabolites were assessed. Glucose-6P, pyruvate, lactate, α-ketoglutarate and citrate were reduced in CSE KO cells, but not in 3MST KO cells, while fumarate and malate were reduced in 3MST KO, but not CSE KO cells. Moreover, extracellular acidification was reduced in EC lacking CSE, but was only minimally affected in 3MST KO EC. In contrast, oxygen consumption rate was more affected in 3MST KO compared to CSE KO cells. In vivo, 3MST expression was mainly observed in the stalk cells, while CSE was highly expressed in the tip cells. Interestingly, only 3MST ablation resulted in reduced pericyte coverage of retinal vessels. Conclusion: We conclude that 3MST and CSE are both required for angiogenesis. 3MST preserves the quiescence of stalk cells by targeting oxidative phosphorylation, while CSE supports tip cell behavior by enhancing their glycolytic capacity.